Compare · CUPR vs NVO
CUPR vs NVO
Side-by-side comparison of Cuprina Holdings (Cayman) Limited (CUPR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CUPR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- Over the past year, CUPR is down 93.2% and NVO is down 34.2% - NVO leads by 59.0 points.
- CUPR has been more active in the news (7 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for CUPR).
- Company
- Cuprina Holdings (Cayman) Limited
- Novo Nordisk A/S
- Price
- $0.30-0.53%
- $41.18+6.93%
- Market cap
- -
- $220.35B
- 1M return
- -4.56%
- +13.32%
- 1Y return
- -93.24%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 7
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CUPR
- SEC Form 3 filed by new insider Lee Jimmy Peng Siew
- SEC Form 3 filed by new insider Raina Natasha Kaur
- SEC Form 3 filed by new insider Teo Peng Kwang
- SEC Form 3 filed by new insider Koh Pee Keat
- SEC Form 3 filed by new insider Quek David Yong Qi
- SEC Form 3 filed by new insider Chan Tat Jing
- SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited
- SEC Form 3 filed by new insider Ng Wei Chean
- SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited
- Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia and Strengthens Global Scientific Advisory Board
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S